Clinical Study

Platinum Chemotherapy Vs. Capecitabine In Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Posted Date: Sep 25, 2019

  • Investigator: Neetu Radhakrishnan
  • Specialties: Breast Cancer, Cancer
  • Type of Study: Drug

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.


Residual Disease In Breast ( After Chemotherapy) Of 1Cm Or More


Triple Negative Breast Cancer Stage 2 Or 3, Residual Disease After Chemotherapy, After Neoadjuvant Chemotherapy

For More Information:

Laura Bundus

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.